NASDAQ · TENX
Tenax Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TENX: Nov 11, 2026
Tenax Therapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.35. The reported EPS for the same quarter last year was $-0.4.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.35 | $-0.33 | $-0.37 | 3 |
| Dec 2026 | $-0.36 | $-0.34 | $-0.40 | 3 |
| Mar 2027 | $-0.37 | $-0.33 | $-0.41 | 2 |
| Jun 2027 | $-0.37 | $-0.35 | $-0.39 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · MarketBeat · Zacks- BNK Invest · Sep 21, 1:36 PM EDTMonday 9/21 Insider Buying Report: TH, TENXBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today
- RTTNews · Aug 30, 6:03 PM EDTTenax's Phase 3 Study For TNX-103 Fails To Meet Primary Endpoint; Shows Success In Other Measures(RTTNews) – Tenax Therapeutics Inc. (TENX), a development-stage pharmaceutical company, on Friday announced clinical results from the Phase 3 LEVEL trial for TNX-103 in patients with pulmonary hypertension associated with heart failure preserved ejection fraction. The data was pr
- RTTNews · Aug 25, 3:34 PM EDTBiotech Gainers: TENX Rebound, KURA Momentum, AVXL Profit, RNXT Data Drive Gains(RTTNews) – Today's top gainers in the biotech and healthcare space include Tenax Therapeutics, following a sharp rebound despite its recent Phase 3 trial setback; Kura Oncology, on continued Komzifti adoption; Anavex Life Sciences, after returning to profitability; Immatics, fol
- RTTNews · Aug 24, 10:07 PM EDT5 After-Hours Healthcare Gainers: AMIX, PMI, TENX, KURA, NEPH(RTTNews) – The after-hours gainers on Monday included Autonomix Medical, following its recent reverse stock split; Picard Medical, which reported encouraging Q2 results recently; and Tenax Therapeutics, now showing signs of recovery after plunging 90% earlier this month, among o
- MarketBeat · Aug 11, 2:01 AM EDTTenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan CaseTenax Therapeutics (NASDAQ:TENX) reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup,
- RTTNews · Jul 31, 10:24 AM EDTTenax Posts Wider Q2 Loss; Phase 3 Heart Drug Results Due In August(RTTNews) – Tenex Therapeutics (TENX) on Friday reported second-quarter results, reflecting a wider net loss for the quarter ended June 30, 2026.
- Zacks · Jul 21, 9:55 AM EDTWall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should KnowThe mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Fintel · Mar 26, 11:14 PM EDTTenax Therapeutics (TENX) Price Target Increased by 13.86% to 29.32The average one-year price target for Tenax Therapeutics (NasdaqCM:TENX) has been revised to $29.32 / share. This is an increase of 13.86% from the prior estimate of $25.76 dated February 21, 2026. The price target is an average of many targets provided by ana
- Fintel · Mar 17, 6:04 PM EDTCantor Fitzgerald Initiates Coverage of Tenax Therapeutics (TENX) with Overweight RecommendationFintel reports that on March 17, 2026, Cantor Fitzgerald initiated coverage of Tenax Therapeutics (NasdaqCM:TENX) with a Overweight recommendation. Analyst Price Forecast Suggests 84.23% Upside
- Fintel · Dec 20, 7:59 PM ESTTenax Therapeutics (TENX) Price Target Increased by 12.22% to 25.76The average one-year price target for Tenax Therapeutics (NasdaqCM:TENX) has been revised to $25.76 / share. This is an increase of 12.22% from the prior estimate of $22.95 dated December 3, 2025. The price target is an average of many targets provided by anal
- Fintel · Dec 17, 6:57 PM ESTGuggenheim Maintains Tenax Therapeutics (TENX) Buy RecommendationFintel reports that on December 17, 2025, Guggenheim maintained coverage of Tenax Therapeutics (NasdaqCM:TENX) with a Buy recommendation. Analyst Price Forecast Suggests 94.82% Upside
- The Motley Fool · Aug 13, 6:03 PM EDTTenax Posts Wider Loss in Fiscal Q2Net loss totaled $10.85 million for Q2 2025, compared to $3.6 million in Q2 2024.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Tenax Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.